All In Biotech

Drug Trial Radar · NCT04164901

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 331 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

331

Actual

Start

Jan 5, 2020

Primary completion

Sep 6, 2022

Study completion May 2028

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.

Conditions

  • Grade 2 Glioma
  • Residual Glioma
  • Recurrent Glioma

Interventions

  • VorasidenibDrug

    Vorasidenib oral film-coated tablets

  • Matching PlaceboDrug

    Matching Placebo oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 30 months

Locations

84 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • University of California San Diego

    La Jolla, California

  • UCLA Oncology Center

    Los Angeles, California

  • University of California Irvine - Hospital

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • Stanford Cancer Center

    Stanford, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • Yale University, Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center - University of Miami Hospital and Clinics

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University Medical Center

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Maine Medical Partners Neurology

    Scarborough, Maine

  • John Hopkins Cancer Center

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Metro Minnesota Community Oncology

    Minneapolis, Minnesota

  • Mayo Comprehensive Cancer

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Tennessee Oncology

    Nashville, Tennessee

  • Baylor University Medical Center

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • The University of Utah, Huntsman Cancer Hospital

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.